Standalone and Consolidated Financial Results for the Quarter and Financial Year ended 31st March 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts more than Nifty Microcap 250 and 2.0 pts more than its Industrial Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Trans India House Impex Limited reported FY2025-26 standalone revenue of Rs 7,105.20 Lakhs, a sharp 100% increase from Rs 3,552.60 Lakhs in the prior year. Standalone PAT grew to Rs 210.21 Lakhs (vs Rs 143.50 Lakhs), a ~46.5% rise. However, Q4 standalone PAT collapsed to just Rs 2.20 Lakhs from Rs 159.48 Lakhs a year ago, indicating a severe second-half slowdown. Consolidated PAT stood at Rs 266.21 Lakhs. Operating cash flow was deeply negative at Rs 5,105.09 Lakhs (vs positive Rs 41.24 Lakhs in FY25), driven by a massive Rs 3,481.25 Lakhs increase in trade receivables. The statutory auditors (Manoj Acharya & Associates) issued an unmodified opinion but raised an Emphasis of Matter on four issues: (1) an Income Tax assessment order (March 2026) adding long-standing receivables/payables to taxable income for FY23-24 with penalty proceedings initiated; (2) pending appeal outcome with unascertainable financial impact; (3) suspicious concentration of sales in March 2026; and (4) unconfirmed trade debtor balances affecting recoverability. A new internal auditor (Agarwal Akshay & Associates) was also appointed for FY27. Trade receivables surged to Rs 13,137.12 Lakhs from Rs 2.20 Lakhs, a major red flag.
The company shows strong headline revenue and PAT growth but is undermined by a severe Q4 PAT collapse, deeply negative operating cash flow, a massive jump in trade receivables, and unresolved tax/audit concerns. The Emphasis of Matter and suspicious March sales spike may attract regulatory scrutiny. Investors should treat the strong FY numbers with caution given cash flow deterioration and audit qualifications.